...
首页> 外文期刊>Drug delivery. >Intranasal brain-targeted clonazepam polymeric micelles for immediate control of status epilepticus: in vitro optimization, ex vivo determination of cytotoxicity, in vivo biodistribution and pharmacodynamics studies
【24h】

Intranasal brain-targeted clonazepam polymeric micelles for immediate control of status epilepticus: in vitro optimization, ex vivo determination of cytotoxicity, in vivo biodistribution and pharmacodynamics studies

机译:鼻内靶向氯硝西am的聚合物胶束可立即控制癫痫持续状态:体外优化,离体确定细胞毒性,体内生物分布和药效学研究

获取原文
           

摘要

Abstract Clonazepam (CZ) is an anti-epileptic drug used mainly in status epilepticus (SE). The drug belongs to Class II according to BCS classification with very limited solubility and high permeability and it suffers from extensive first-pass metabolism. The aim of the present study was to develop CZ-loaded polymeric micelles (PM) for direct brain delivery allowing immediate control of SE. PM were prepared via thin film hydration (TFH) technique adopting a central composite face-centered design (CCFD). The seventeen developed formulae were evaluated in terms of entrapment efficiency (EE), particle size (PS), polydispersity index (PDI), zeta potential (ZP), and in vitro release. For evaluating the in vivo behavior of the optimized formula, both biodistrbution using 99mTc-radiolabeled CZ and pharmacodynamics studies were done in addition to ex vivo cytotoxicty. At a drug:Pluronic? P123:Pluronic? L121 ratio of 1:20:20 (PM7), a high EE, ZP, Q8h, and a low PDI was achieved. The biodistribution studies revealed that the optimized formula had significantly higher drug targeting efficiency (DTE?=?242.3%), drug targeting index (DTI?=?144.25), and nose-to-brain direct transport percentage (DTP?=?99.30%) and a significant prolongation of protection from seizures in comparison to the intranasally administered solution with minor histopathological changes. The declared results reveal the ability of the developed PM to be a strong potential candidate for the emergency treatment of SE.
机译:摘要氯硝西am(CZ)是一种主要用于癫痫持续状态(SE)的抗癫痫药。该药物根据BCS分类属于II类,具有非常有限的溶解度和高渗透性,并且具有广泛的首过代谢。本研究的目的是开发用于直接脑部递送的CZ负载聚合物胶束(PM),从而可以立即控制SE。通过采用中央复合面心设计(CCFD)的薄膜水化(TFH)技术制备PM。根据包封效率(EE),粒度(PS),多分散指数(PDI),ζ电位(ZP)和体外释放评估了十七种开发的配方。为了评估优化配方的体内行为,除了使用离体细胞毒性外,还进行了使用 99m Tc放射性标记的CZ的生物分布和药效学研究。在使用药物:Pluronic? P123:Pluronic? L121比率为1:20:20(PM7),具有较高的EE,ZP,Q8h和较低的PDI。生物分布研究表明,优化的配方具有明显更高的药物靶向效率(DTEα=?242.3%),药物靶向指数(DTIα=?144.25)和鼻-脑直接转运百分比(DTPβ=?99.30%)。与鼻腔给药溶液相比,具有轻微的组织病理学变化,可显着延长对癫痫发作的保护作用。宣布的结果表明,已开发的PM成为SE紧急治疗的强大潜在候选人的能力。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号